Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Hybrid Capture Tech for HLA Testing Receives CE Marking

NEW YORK – CareDx said on Friday that it has received CE marking for its AlloSeq Tx 17 HLA typing product.

AlloSeq Tx 17, which the company launched in September 2019, is used to match transplant donor organs to recipients using next-generation hybrid capture technology for HLA testing. During CareDx's fourth quarter earnings conference call in February, Chairman and CEO Peter Maag said that the company expects the AlloSeq Tx HLA typing product to start driving product revenues this year, and that it received high marks from beta testers before it was officially launched.

"AlloSeq Tx 17 eliminates PCR disadvantages such as allele drop out and provides a simple workflow that could be easily implemented in histocompatibility and immunogenetics laboratories," Milena Ivanova-Shivarova, lab manager of Alexandrovska University Hospital, said in a statement. "Generation of reliable data and ability to extend the typing to additional non-classical HLA loci will provide better care for patients."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.